metricas
covid
Buscar en
Endocrinología, Diabetes y Nutrición (English ed.)
Toda la web
Inicio Endocrinología, Diabetes y Nutrición (English ed.) Phone coaching, glycemic control and diabetes unit visits in patients treated wi...
Información de la revista
Vol. 64. Núm. 6.
Páginas 328-329 (junio - julio 2017)
Vol. 64. Núm. 6.
Páginas 328-329 (junio - julio 2017)
Scientific letter
Acceso a texto completo
Phone coaching, glycemic control and diabetes unit visits in patients treated with insulin
Apoyo telefónico, control glucémico y visitas a la unidad de diabetes en pacientes insulinizados
Visitas
1539
Begoña Sánchez Lechugaa,
Autor para correspondencia
bsanchezle@gmail.com

Corresponding author.
, Florentino Carral San Laureanob, Carmen Ayala Ortegab, Antonia Piñero Zaldivarb, Coral Expósito Carbalb
a Servicio de Endocrinología y Nutrición, Hospital Universitario Puerta del Mar, Cádiz, Spain
b Servicio de Endocrinología y Nutrición, Hospital Universitario Puerto Real, Cádiz, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

Type 2 diabetes (DM2) is a chronic disorder of increasing prevalence throughout the world and requires permanent attention from health professionals as well as patient self-care in order both to avoid acute complications and to lessen the risk of late complications of the disease.1 In this regard, most patients with DM2 subjected to insulin therapy can derive benefit from a regime of personal autonomy supervised by the health professional. This allows patients to be as independent as possible while avoiding incorrect insulin dose adjustments, and also ensuring that any other decisions made by the patient are adequately validated. Such support is particularly important in periods of poor metabolic control (e.g., at the start of insulinization), when continuous therapeutic revisions are needed. Such revisions cannot always be made on a physical presence basis, particularly in healthcare recruitment areas characterized by important population dispersion or with patients who have transport problems for economic, occupational or health reasons.2,3 Different systematic reviews and meta-analyses support the effectiveness of telephone support in the metabolic control of diabetic patients.3–8 In this regard, the Andalusian Health Technologies Evaluation Agency (Agencia de Evaluación de Tecnologías Sanitarias de Andalucía) (Spain) recommends the use of mobile phones and SMS communication for the intensive monitoring of diabetic patients, and points to the need for clinical effectiveness trials to demonstrate that this kind of monitoring is at least as effective as physical attendance.9

In the Diabetes Unit of Hospital Universitario Puerto Real (Cádiz, Spain) we have a shared care protocol involving health professionals and diabetes educators for type 2 diabetic patients with poor metabolic control who start or intensify insulin treatment. The protocol requires either personal visits to the Diabetes Day Hospital or scheduled phone contacts by the health educator every 15–30 days until optimum glycemic control has been achieved. The monitoring mode is chosen by the patient according to his or her needs. Independently of whether personal visiting or telephone monitoring is preferred, all the patients attending our Unit can contact our Day Hospital if necessary. A descriptive observational study has been carried out to evaluate the effectiveness of the protocol in terms of metabolic control and the number of contacts and visits to the Diabetes Unit according to the monitoring mode used. The study consisted of 154 patients (mean age 64.7±11.6 years; 53% females) with DM2 (mean duration 13.9±10.1) and poor metabolic control (mean HbA1c concentration 10.4±1.3%) who started or intensified insulin treatment in the previous year and were followed-up for at least 6 months. Two cohorts were examined: physical presence monitoring (84 patients; 55% of the total) and phone monitoring (70 patients; 45% of the total). There were no baseline differences between the two groups for any of the clinical variables analyzed, except smoking, which was more prevalent in the physical presence group (22% vs 9%, p=0.02).

The patients in the physical presence and phone coaching groups showed similar HbA1c levels at baseline (10.2±1.3 vs 10.5±1.4%) and after 3 months (8.8±1.2 vs 9.1±1.1%) and 6 months of follow-up (8.1±1.2 vs 8.3±1.1%). The differences were not statistically significant. However, the patients in the phone monitoring group made comparatively fewer visits to the physician (mean 3.3±1.0 vs 2.5±0.7 visits during follow-up; p=0.001) and health educator (mean 3.8±1.0 vs 1.7±1.0 visits during follow-up; p<0.001), at the expense of a greater number of phone calls to the Diabetes Day Hospital (mean 1.9±0.9 vs 0.2±0.3 calls during follow-up; p<0.001).

In conclusion, our results support the idea that the effectiveness of phone monitoring of poorly controlled diabetics in improving metabolic control is similar to that of physical presence monitoring,6–8 while requiring fewer visits to the healthcare center. This may possibly contribute both to improving levels of patient satisfaction and to reducing the indirect costs associated with unnecessary patient visits. Lastly, the telephone support of diabetic patients can probably contribute to improving patient self-management of insulin therapy and diabetes education, favoring increased diabetes self-care, under the supervision of health professionals.10

Financial support

This study was partially financed by an “Innovating in chronic patient care” grant from Laboratorios Esteve.

Conflicts of interest

The authors state that they have no conflicts of interest.

References
[1]
American Diabetes Association.
Standards of medical care in diabetes.
Diabetes Care, 39 (2016), pp. S39-S46
[2]
F. Carral, C. Ayala, A.I. Jiménez, A. Piñero, C. García, M. Prieto.
Página Web DiabeTIC: Estudio piloto de la satisfacción e impacto sobre el control metabólico.
Endocrinol Nutr, 60 (2013), pp. 441-446
[3]
Y.K. Zhai, W.J. Zhu, Y.L. Cai, D.X. Sun, J. Zhao.
Clinical and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis.
Medicine (Baltimore), 93 (2014), pp. 1-11
[4]
X. Liang, Q. Wang, X. Yang, J. Cao, J. Chen, X. Mo, et al.
Effect of mobile phone intervention for diabetes on glycaemic control: a meta-analysis.
Diabet Med, 28 (2011), pp. 455-463
[5]
Z. Huang, H. Tao, Q. Meng, L. Jing.
Management of endocrine disease. Effects of telecare intervention on glycemic control in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Eur J Endocrinol, 172 (2015), pp. R93-R101
[6]
N. Suksomboon, N. Poolsup, Y.L. Nge.
Impact of phone call intervention on glycemic control in diabetes patients: a systematic review and metaanalysis of randomized, controlled trials.
PLOS ONE, 9 (2014), pp. 1-7
[7]
B. Holtz, C. Lauckner.
Diabetes management via mobile phones: a systematic review.
Telemed J E Health, 18 (2012), pp. 175-184
[8]
A. Peterson.
Improving type 1 diabetes management with mobile tools: a systematic review.
J Diabetes Sci Technol, 8 (2014), pp. 859-864
[9]
S. Márquez, R. Canto.
Telemedicina en el seguimiento de enfermedades crónicas: Diabetes Mellitus. Revisión sistemática y evaluación económica.
Agencia de Evaluación de Tecnologías Sanitarias de Andalucía/Ministerio de Sanidad y Consumo, (2008),
[10]
D.C. Klonoff.
Using telemedicine to improve outcomes in diabetes – an emerging technology.
J Diabetes Sci Technol, 3 (2009), pp. 624-628

Please cite this article as: Sánchez Lechuga B, Carral San Laureano F, Ayala Ortega C, Piñero Zaldivar A, Expósito Carbal C. Apoyo telefónico, control glucémico y visitas a la unidad de diabetes en pacientes insulinizados. Endocrinol Nutr. 2017;64:328–329.

Copyright © 2017. SEEN and SED
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.endien.2021.11.020
No mostrar más